Development In-Vivo Protein Reagent 
Drug Discovery World
APRIL 3, 2023
DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would one day be operating on such a global scale? I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development.
Drug Discovery World
OCTOBER 13, 2022
Over the two days at ExCel, 1554 delegates attended the event. Of those delegates, 75% work in drug discovery. There were 127 exhibitors, 180 posters, 40 technology speakers, 52 scientific speakers as well as a series of eight seminars focused on automation and technology which DDW organised and moderated in the dedicated Tech Theatre. .
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
NOVEMBER 30, 2023
Lightcast is developing a novel, programmable microfluidic platform that allows precise and highly flexible control of individual microdroplets using software-generated light patterns. This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It
XTalks
APRIL 22, 2022
Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. All drug development processes evaluate a drug’s pharmacokinetics (PK) to gather data about its absorption, distribution, metabolism, and excretion in the body.
Drug Discovery World
JULY 18, 2023
Years of development and fast-paced research have continued to unlock its potential, expanding how CRISPR can be used to treat, detect, and prevent common diseases such as cancer and Covid-19. Rolf Turk , Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies.
Drug Discovery World
DECEMBER 15, 2022
Potential solutions: For CRISPR systems, the likelihood of off-target editing has been shown to be influenced by a variety of factors, ranging from the design of the gRNA 1 and Cas9 protein 2 , to the targeted cell type 3 , to name a few examples. In vivo approaches involve delivering the gene editing components directly into the patient.
Drug Discovery World
DECEMBER 13, 2023
In the ever-evolving landscape of therapeutic development, the role of antibodies has become increasingly apparent. Moreover, custom antibodies are a key reagent in companion diagnostics for these novel therapeutics. This article is sponsored by Fortis Life Sciences.
Expert insights. Personalized for you.
52 
Let's personalize your content